



1. Maughn K, Achter E, Liu Y. Characteristics, healthcare resource utilization and costs among Medicaid-insured adults with hepatitis delta virus: An analysis of US all-payer medical and pharmacy claims data. *ISPOR European Congress 2022*. Vienna, Austria: Nov 6-9, 2022
2. Maughn K, Afolabi M, Michael-Asalu A, Chopra I. Impact of patient race on insurance payor switch rate, healthcare resource utilization, and cost among adult patients with schizophrenia in the United States: An analysis of RWD Insights all payer claims database. *ISPOR Annual European Congress*. Vienna, Austria: Nov 6-9, 2022.
3. Kang A, Noxon V, Atreja N, et al. Racial disparities and geographic variation in anticoagulant treatment among Medicare beneficiaries with non-valvular atrial fibrillation in the United States. *American Heart Association (AHA) Scientific Sessions 2022*. Chicago, IL: Nov 5-7, 2022.
4. Zhao R, Ding Z, Gupta P, et al. Evaluation of treatment patterns among Crohn's disease patients initiating biologics with three years of follow-up. *American College of Gastroenterology (ACG) Annual Scientific Meeting*. Charlotte, NC: Oct 21-26, 2022.
5. Wong R, Gish RG, Lim J, et al. Increased comorbidity burden among HDV infection versus HBV mono-infection among commercially insured adults in the United States: An all-payer claims database analysis. *Academy of Managed Care Pharmacy (AMCP) Nexus 2022*. National Harbor, MD: Oct 11-14, 2022.
6. Maughn K, Achter E, Liu Y. Characteristics, healthcare resource utilization and costs among Medicaid-Insured adults with hepatitis delta virus: An analysis of all-payer medical and pharmacy claims data. *Academy of Managed Care Pharmacy (AMCP) Nexus 2022*. National Harbor, MD: Oct 11-14, 2022. **(GOLD RIBBON AWARD)**
7. Maughn K, Afolabi M, Michael-Asalu A, Chopra I. Impact of patient race on insurance payor switch rate, healthcare resource utilization, and cost among adult patients with schizophrenia in the United States: An analysis of RWD Insights all payer claims database. *Academy of Managed Care Pharmacy (AMCP) Nexus 2022*. National Harbor, MD: Oct 11-14, 2022.
8. Leo S, Maughn K, Miller A, et al. Tardive dyskinesia: Epidemiological trends in US populations based on cross-sectional analysis of retrospective claims data. *35th Annual Psych Congress*. New Orleans, LA: Sept 17-20, 2022.
9. Wu J, Hassan M, Cyhaniuk A, et al. Reduction in hospitalizations following initiation of amikacin liposome inhalation suspension: A retrospective cohort study of patients in real-world settings. *2022 Eastern Pulmonary Conference*. Palm Beach, FL: Sept 8-11, 2022. (Encore)
10. Dhamane AD, Noxon V, Bruette R, et al. Anticoagulant treatment patterns and thromboembolic events by tumor type among patients with VTE and cancer. *European Society of Cardiology (ESC) Congress 2022*. Barcelona, Spain: Aug 26-29, 2022.
11. Worden C, Shoaib-Agwan S, Singh R, Zhang W. Comparison of clinical and economic burden of pulmonary arterial hypertension patients with and without connective tissue disease treated with macitentan. *European Society of Cardiology (ESC) Congress 2022*. Barcelona, Spain: August 26-29, 2022.
12. Shah S, Dhamane A, Bruette R, et al. Factors associated with anticoagulant treatment initiation among venous thromboembolism patients with cancer. *International Society on Thrombosis and Haemostasis (ISTH) Congress*. London, UK: July 9-13, 2022.



13. Lim J, Rustgi V, Gish R, et al. Healthcare resource utilization and costs of hepatitis delta in the United States: an analysis of All-Payer Claims Database. *EASL International Liver Congress 2022*. June 22-26, 2022.
14. Wong R, Gish R, Lim J, et al. Hepatitis delta management in the United States: An analysis of All-Payer Claims Data. *EASL International Liver Congress 2022*. June 22-26, 2022.
15. Gish R, Jacobson I, Lim J, et al. Evaluating hepatitis delta virus disease prevalence and patient characteristics among adults in the United States: An analysis of an All-Payer Claims Database. *EASL International Liver Congress 2022*. June 22-26, 2022.
16. Navari RM, Nelson WW, Utt JT, et al. Real-world treatment outcomes and healthcare resource use associated with antiemetics among cancer patients on highly emetogenic platinum-based chemotherapy. *American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL: June 3-7, 2022. (online abstract)
17. Gish RG, Jacobson I, Lim JK, et al. Hepatitis delta among commercially insured patients in the United States: An analysis of prevalence, patient characteristics, and socioeconomic status. *Digestive Disease Week (DDW) 2022*. San Diego, CA + virtual: May 21-24, 2022.
18. Wong R, Gish RG, Lim JK, et al. Increased comorbidity burden among HDV infection versus HBV mono-infection among commercially insured adults in the United States: An All-Payer Claims Database analysis. *Digestive Disease Week (DDW) 2022*. San Diego, CA + virtual: May 21-24, 2022.
19. Dhamane A, Ferri M, Keshishian A, et al. Healthcare costs of direct oral anticoagulants among Medicare patients with nonvalvular atrial fibrillation and multimorbidity. *ISPOR Annual Meeting 2022*. National Harbor, Washington, DC: May 14-18, 2022.
20. Pennell N, Clarke J, Liu SV, et al. Ramucirumab + docetaxel post immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy (chemo) in advanced or metastatic non-small cell lung cancer (aNSCLC): Learnings from the TREAT-LUNG Observational Study. *ISPOR Annual Meeting 2022*. National Harbor, Washington, DC: May 14-18, 2022.
21. Cyhaniuk A, Zhao R, Ding Z, et al. Evaluation of health care resource utilization and costs among bio naïve Crohn's disease patients initiating biologics with two years of follow-up. *ISPOR Annual Meeting 2022*. National Harbor, Washington, DC: May 14-18, 2022.
22. Cyhaniuk A, Zhao R, Ding Z, Gupta P, Kachroo S. Evaluation of health care resource utilization and costs among bio-experienced Crohn's disease patients treated with biologics with two years of follow-up. *ISPOR Annual Meeting 2022*. National Harbor, Washington, DC: May 14-18, 2022.
23. Qiu Y, Zhu J, Elpers B, et al. Antifibrotic treatment prevalence, clinical outcomes, and economic burden among veterans with idiopathic pulmonary fibrosis (IPF) in the United States. *American Thoracic Society (ATS) International Conference*. San Francisco, CA. May 13-18, 2022.



24. Wu J, Hassan M, Cyhaniuk A, et al. Reduction in hospitalizations following initiation of amikacin liposome inhalation suspension: A retrospective cohort study of patients in real-world settings. *American Thoracic Society (ATS) International Conference*. San Francisco, CA. May 13-18, 2022. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2022.205.1_MeetingAbstracts.A3866
25. Tsang Y, Verma S, Singh R, Panjabi S. The effectiveness of selexipag in pulmonary arterial hypertension patients with and without associated connective tissue disease comorbidity in United States. *American Thoracic Society (ATS) International Conference*. San Francisco, CA. May 13-18, 2022.
26. Agapova M, Tangirala K, Pedarla V, et al. Real-world impact of fremanezumab use on clinical outcomes among migraine patients with comorbid depression, anxiety, or hypertension. *Academy of Managed Care Pharmacy (AMCP) Spring Meeting 2022*. Chicago, IL: Mar 29-Apr 1, 2022.
27. Bell CF, Huang SP, Cyhaniuk A, Averell C. Economic burden of flares in patients with systemic lupus erythematosus with and without lupus nephritis in the United States. *State of Texas Association of Rheumatologists (STAR) Annual Meeting*. Houston, TX: Feb 25-27, 2022.
28. Boytsov N, Cyhaniuk A, Leung G, et al. A retrospective database analysis of treatment pathways in US Medicare patients with multiple myeloma with prior exposure to daratumumab, an immunomodulatory agent, and a proteasome inhibitor. *American Society of Hematology (ASH) Annual Meeting and Exposition*. Atlanta, GA: Dec 11-14, 2021.
29. Lip GYH, Murphy RR, Sahiar F, et al. Contemporary evidence on risk stratification of anticoagulated non-valvular atrial fibrillation patients grouped by CHA₂D₂-VASc score levels. *American Heart Association (AHA) Scientific Sessions*. Boston, MA + Virtual: Nov 13-15, 2021.
30. Gish R, Jacobson I, Lim J, et al. Prevalence and characteristics of hepatitis delta in the United States: An analysis of all-payer claims database. *AASLD - The Liver Meeting*. Anaheim, CA + virtual: Nov 12-15, 2021.
31. Jacobson I, Gish R, Lim J, et al. Higher baseline comorbidities and liver complications among patients with hepatitis delta infection versus hepatitis B mono-infection: A national US claims database analysis. *AASLD - The Liver Meeting*. Anaheim, CA + virtual: Nov 12-15, 2021.
32. Tangirala K, Pedarla V, Driessen M, et al. Impact of AJOVY use on clinical outcomes among migraine patients with comorbid depression, anxiety, or hypertension in a real-world setting. *Psych Congress*. San Antonio, TX: Oct 29-Nov 1, 2021.
33. Chopra I, Rock M, Mezzio D. Persistence on guideline-recommended HIV treatment: comparison among US Medicaid beneficiaries newly initiating treatment with single-versus multiple-tablet regimens. *18th European AIDS Conference*. Oct 27-30, 2021.
34. Muser E, Teeple A, Sah J, et al. Treatment patterns among Crohn's disease patients initiating biologics: A two-year pooled analysis of three United States claims databases. *American College of Gastroenterology (ACG) Annual Scientific Meeting*. Las Vegas + Virtual (Hybrid): Oct 22-27, 2021.



35. Muser E, Teeple A, Sah J, et al. Treatment patterns in Crohn's disease patients who initiated treatment with ustekinumab in the United States. *Academy of Managed Care Pharmacy (AMCP) Nexus 2021*. Denver, CO: Oct 19-21, 2021.
36. Qiu Y, Zhu J, Elpers B, et al. Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis. *European Respiratory Society (ERS) International Congress*. Vienna, Austria: Sept 5-8, 2021.
37. Deitelzweig S, Keshishian A, Kang A, et al. Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin. *ESC 2021*. Online only: Aug 27-30, 2021.
38. Deitelzweig S, Keshishian A, Kang A, et al. Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants: An ARISTOPHANES analysis. *ESC 2021*. Virtual: Aug 27-30, 2021.
39. Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among nonvalvular atrial fibrillation patients with prior bleeding events. *ESC 2021*. Virtual: Aug 27-30, 2021.
40. Cohen A, Sah J, Dhamane A, et al. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients stratified by race. *ESC 2021*. Virtual: Aug 27-30, 2021.
41. Cohen A, Sah J, Dhamane A, et al. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: a subgroup analysis of chronic liver disease. *ESC 2021*. Online only: Aug 27-30, 2021.
42. Cohen A, Sah J, Dhamane A, et al. Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients: A subgroup analysis of age. *ESC 2021*. Virtual: August 27-30, 2021.
43. Dhamane AD, Keshishian A, Preib MT, et al. Burden and costs of stroke/systemic embolism and major bleeding among elderly non-valvular atrial fibrillation patients prescribed oral anticoagulants. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
44. Cohen A, Sah J, Dhamane A, et al. Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients using five US databases: A subgroup analysis of thrombophilia. *ISTH 2021 Hematology Conference*. Phil, PA: July 17-21, 2021.
45. Preib MT, Wang Y, Mitrani-Gold FS, et al. Treatment patterns among females with uncomplicated urinary tract infections pre- and post-issue of a Food and Drug Administration warning for fluoroquinolone-associated serious adverse events. *31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)*. July 9-12, 2021.
46. Munir MB, Hlavacek P, Keshishian A, et al. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.
47. Atwater B, Di Fusco M, Keshishian A, et al. Geographic variation in anticoagulation among Medicare beneficiaries with non-valvular atrial fibrillation in the United States. *Heart Rhythm Society (HRS) 2021*. June 30: Virtual kick-off, In-person: July 28-31.



48. Russell-Smith TA, Verma S, Liu Y, et al. Retrospective real-world comparison of clinical and economic burden between first-generation and second-generation tyrosine kinase inhibitors in chronic myeloid leukemia. *European Hematology Association (EHA) Virtual 2021 Congress*. June 9, 2021.
49. Liu J, Thaker PH, Sah J, et al. Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change? *2021 American Society of Clinical Oncology ASCO Annual Meeting*. June 4-5, 2021. (online abstract)
50. Liu J, Chan J, Sah J, et al. Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: does maintenance therapy work? *2021 American Society of Clinical Oncology ASCO Annual Meeting*. June 4-5, 2021. (online abstract)
51. Smith TA, Verma S, Liu Y, et al. Retrospective real-world comparison of clinical and economic burden between first generation and second-generation tyrosine kinase Inhibitors in chronic myeloid leukemia. *2021 American Society of Clinical Oncology (ASCO) Annual Meeting*. June 4-5, 2021.
52. Petri M, Naessens D, Ogbomo A, et al. Epidemiology and economic burden associated with mental health comorbidities in systemic lupus erythematosus and lupus nephritis patients. *EULAR 2021 Annual European Congress of Rheumatology*. June 2-5, 2021.
53. Teeple A, Sah J, Mallampati R, et al. Treatment patterns in biologic-experienced Crohn's disease patients using three large commercial claims databases in the United States. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
54. Sah J, Teeple A, Muser E, et al. Treatment patterns of biologic agents in ulcerative colitis: A pooled study of three United States claim databases. *Digestive Disease Week (DDW) 2021*. Virtual: May 21-23, 2021.
55. Siegel CA, Seigel L, Verma S, et al. Current landscape and treatments used in patients with moderate-to-severe ulcerative colitis. *Virtual ISPOR 2021*. May 17-20, 2021.
56. Maughn K, Chen J, Nelson DR, et al. Trajectory of glycosylated hemoglobin over time among obese type 2 diabetes patients prescribed U-100 basal-only insulin regimens: A US administrative claims data analysis. *Virtual ISPOR 2021*. May 17-20, 2021.
57. Leist T, Le H, Verma S, et al. Real world adherence, persistence, relapse and multiple sclerosis symptoms among patients treated with oral disease-modifying therapies. *Virtual ISPOR 2021*. May 17-20, 2021.
58. Ogbomo A, Tsang Y, Jaiswal M, et al. Examining the direct and indirect healthcare cost among pulmonary arterial hypertension patients. *Virtual ISPOR 2021*. May 17-20, 2021.
59. Dhamane A, Ferri M, Keshishian A, et al. Effectiveness and safety of direct oral anticoagulants among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
60. Munir B, Hlavacek P, Keshishian A, et al. Underutilization of oral anticoagulant therapy among elderly patients with atrial fibrillation: Insights from the United States Medicare database. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.



61. Turakhia M, Guo JD, Keshishian A, et al. Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
62. Deitelzweig S, Sah J, Kang A, et al. Effectiveness and safety of apixaban versus warfarin in obese patients with nonvalvular atrial fibrillation enrolled in Medicare and Veteran Affairs. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
63. Dhamane A, Ferri M, Keshishian A, et al. Direct oral anticoagulants and warfarin: Effectiveness and safety outcomes among nonvalvular atrial fibrillation patients with multimorbidity. *American College of Cardiology (ACC) 70th Annual Scientific Session & Expo*. Atlanta, GA: May 15-17, 2021.
64. Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *British Society of Haematology 2021 Annual Scientific Meeting (Virtual)*. April 25-28, 2021. (Encore)
65. Thompson S, Cohen JM, Tangirala K, et al. Baseline comorbidities and changes in acute medication use by quarterly and monthly dosing regimen in patients prescribed AJOVY in US physician practices. *American Academy of Neurology (AAN) Annual Meeting 2021*. Virtual: April 17-23, 2021.
66. Ogbomo A, Tsang Y, Kariburyo F, et al. Real-world analysis of treatment patterns among hospitalized pulmonary arterial hypertension patients. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
67. Gandhi K, Ray M, Borra S, Sruti I, Xu L. Prevalence and incidence of vitiligo in the United States: A real-world analysis. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
68. Huang H, Schmerold L, Dembek C, et al. Healthcare resource utilization and costs in patients with bipolar disorder treated with lurasidone or cariprazine: A retrospective analysis of insurance claims data. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Francisco, CA: April 13-16, 2021.
69. Chen J, Nelson DR, Borra S, et al. Trajectory of glycated hemoglobin over time among obese type 2 diabetes patients on U-100 basal-bolus insulin regimen using real-world data. *ENDO 2021 (Endocrine Society)*. Virtual: Mar 20-23, 2021.
70. Dawson RS, Saxena K, Ogbomo A. Clinical and economic burden of HPV-related cancers in the US veteran population. *The Association of Military Osteopathic Physicians and Surgeons (AMOPS) 2021 Annual Meeting*. Virtual: Mar 4-7, 2021.
71. Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. *European School of Haematology: 2nd How to Diagnose and Treat CML / MPN*. Virtual: Feb 25–28, 2021.
72. Freedland SJ, Sandin R, Sah J, et al. Survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC): A real-world evidence study. *ASCO 2021 Genitourinary Cancers Symposium*. Virtual: Feb 11-13, 2021.



73. Ogbomo A, Tsang Y, Panjabi S, et al. Examining hospitalization and treatment patterns of pulmonary arterial hypertension patients with and without connective tissue disease using real-world data. *Rheumatology Winter Clinical Symposium (RWCS)*. Maui, HI: Feb 10-13, 2021.
74. Siddiqui MS, Myers J, Byrne C, et al. Real-world healthcare resource utilization and costs among patients with non-alcoholic fatty liver disease are substantial and increase with advanced disease. *American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting*. San Diego, CA: Nov 13-17, 2020.
75. Zhuo J, Zhang Q, Knapp K, et al. Risk factors associated with interstitial lung disease in patients with RA: Findings from a retrospective healthcare database analysis. *ACR Convergence 2020 – American College of Rheumatology All-Virtual Annual Meeting*. Nov 5-9, 2020.
76. Naito T, Wang X, Diaz-Cuervo H, Claxton A. Treatment persistence among treatment-naïve HIV-1 patients initiating antiretroviral therapy in Japan. *APACC 2020 - Asia-Pacific AIDS and Co-Infections Conference*. Oct 15-17, 2020.
77. Tagawa ST, Sandin R, Sah J, et al. Treatment patterns of metastatic castration-sensitive prostate cancer: A real-world evidence study. *European Society for Medical Oncology Virtual Congress 2020*. Sept 19-21, 2020.
78. Castillo JJ, Yang K, Kariburyo F, et al. Clinical and economic burden of mantle cell lymphoma in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*. Sept 12-13, 2020.
79. Castillo JJ, Yang K, Kariburyo F, et al. Real-world evidence on treatment patterns, costs and healthcare resource utilization associated with Waldenström macroglobulinemia in the Veterans Health Administration population. *Association of VA Hematology/Oncology (AVAHO) 2020 "Virtual" Annual Meeting*. Sept 12-13, 2020.
80. Qiu Y, Zhao R, Elpers B, et al. Prevalence and characteristics of patients receiving antifibrotic therapy for idiopathic pulmonary fibrosis. *European Respiratory Society International Congress 2020*. Vienna, Austria: Sept 5-9, 2020.
81. Cohen A, Keshishian A, Lee T, et al. Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer. *European Society of Cardiology (ESC) Congress 2020*. Amsterdam, Netherlands: Aug 29 - Sept 1, 2020.
82. Qiu Y, Byrne C, Tang J, et al. Use of the Fibrosis-4 score to estimate fibrosis stage for patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis in retrospective real-world datasets: A targeted literature review and feasibility assessment. *EASL 2020 International Liver Congress*. London, UK: Aug 27-29, 2020.
83. Huang X, Hovland S, Stange S, et al. Real world disease burden, treatment patterns, and outcomes of hospitalized patients with hepatic encephalopathy. *EASL 2020 International Liver Congress*. London, UK: Aug 27-29, 2020.
84. Muser E, Teeple A, Sah J, et al. Evaluation of inpatient and emergency room utilization and costs among Crohn's disease patients treated with biologics in three large United States commercial claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: June 13-16, 2020.



85. Muser E, Teeple A, Sah J, et al. Concomitant medication utilization among Crohn's disease patients newly initiating biologic therapy from three large commercial insurance claims databases. *Academy Health 2020 Annual Research Meeting*. Boston, MA: June 13-16, 2020.
86. Hood R, Fan L, Pollom RD, et al. Treatment patterns and outcomes before and after human regular U-500 insulin initiation in patients with type 2 diabetes previously on ≤ 200 units/day of insulin. *American Diabetes Association (ADA) 80th Scientific Sessions 2020*. Chicago, IL: June 12-16, 2020.
87. Cazzetta S, Chen G, Pedarla V, et al. Economic impact of perianal fistulizing Crohn's disease in US administrative claims data. *American Society of Colon and Rectal Surgeons (ASCRS) Annual Scientific Meeting*. Boston, MA, June 6-10, 2020.
88. Cohen JM, Pandya S, Krasenbaum LJ, et al. A real-world perspective of patients with episodic migraine or chronic migraine prescribed Ajoovy in the United States. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: June 4, 2020.
89. Cohen JM, Pandya S, Tangirala K, et al. Treatment patterns and characteristics of patients prescribed AJOVY, Emgality, or Aimovig. *American Headache Society 62nd Annual Scientific Meeting*. San Diego, CA: June 4, 2020.
90. Zhuo J, Zhang Q, Knapp K, et al. Examination of interstitial lung disease in patients with rheumatoid arthritis - prevalence, time to onset, and clinical characteristics. *EULAR European Congress of Rheumatology 2020 E-Congress*. June 3-6, 2020.
91. Chen J, Fan L, Pollom RD, et al. Insulin-related out-of-pocket pharmacy costs before and after human regular U-500 insulin initiation via insulin pen in US patients with type 2 diabetes. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
92. Li J, Chen CC, Janjan N, Claxton A. Assessment of economic burden and hospitalization on patients with post-traumatic stress disorder in the US veterans' health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
93. Delinger R, Ratiu A, Xie L, Keshishian A. Assessment of the health care utilization and economic burden on diabetes patients with chronic kidney disease in the US veterans' health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
94. Delinger R, Ratiu A, Xie L, Keshishian A. Comparison of economic burden and risk of hospitalization among HIV patients with and without hepatitis B coinfection in the veterans' health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
95. Sah J, Ratiu A, Gutierrez C, et al. A novel visual tool to understand the treatment patterns among treatment-naïve psoriatic arthritis patients prescribed biologics in the US veterans health administration population. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
96. Sah J, Ratiu A, Gutierrez C, et al. A visual analytical approach to understanding treatment patterns among treatment-naïve rheumatoid arthritis patients with biologic use in the US veterans health administration database. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.
97. Bhanegaonkar A, Pandya S, Kim R, et al. IMPACT RCC Real-World Study: Economic Impact of early progression among PATients with metastatic renal cell Carcinoma treated with Tyrosine kinase inhibitors in first-line setting. *ISPOR 2020*. Orlando, FL: May 16-20, 2020.



98. Muser E, Obando C, Teeple A, et al. Evaluation of biologic treatment patterns among Crohn's disease patients using three large United States claims databases. *DDW Annual Meeting 2020*. Chicago, IL: May 2-5, 2020.
99. Palevsky HI, Pruettt J, Ogbomo A, et al. Examining titration patterns for selexipag in real-world practice using US specialty pharmacy data. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
100. Delinger R, Keshishian A, Li J, et al. Assessment of economic burden and hospitalization on patients with human immunodeficiency virus in the US Veterans Health Administration population. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
101. Gutierrez C, Wang H, Sah J, et al. Evaluating the economic burden and hospitalization among patients with inflammatory bowel disease in the US Veterans Health Administration population. *AMCP 2020 Annual Meeting*. Houston, TX: April 21-24, 2020.
102. Shu FI, Treadwell M, Borra S, et al. Hereditary angioedema and pregnancy complications and outcomes in a population-based cohort. *AAAAI 2020 Annual Meeting*. Philadelphia, PA: March 13-16, 2020.
103. George D, Tagawa S, Lechpammer S, et al. Overall survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving bicalutamide followed by enzalutamide or abiraterone. *ASCO GU 2020*. San Francisco, CA: Feb 13-15, 2020.
104. Cohen AT, Keshishian A, Lee T, et al. Safety and effectiveness of apixaban compared to warfarin among venous thromboembolism patients with active cancer: A retrospective analysis using four US claims databases. *61st American Society of Hematology (ASH) Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
105. Cohen AT, Keshishian A, Lee T, et al. Safety and effectiveness of apixaban, LMWH and warfarin among venous thromboembolism (VTE) patients with active cancer: A subgroup analysis of VTE risk scale. *61st ASH Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
106. Levy M, Xie L, Wang Y, et al. Major adverse cardiac, arterial occlusive, and venous occlusive events among chronic myeloid leukemia patients prescribed ponatinib vs bosutinib in a real-world setting. *61st ASH Annual Meeting and Exposition*. Orlando, FL: Dec 7-10, 2019.
107. Keshishian A, Wiederkehr D, Li X, et al. Patterns of oral anticoagulant treatment among non-valvular atrial fibrillation patients with end-stage renal disease treated with dialysis. American Heart Association (AHA) Scientific Sessions. Philadelphia, PA: Nov 16-18, 2019.
108. Bhanegaonkar A, Kim R, Pandya S, et al. Real-world treatment patterns among patients with metastatic renal cell carcinoma receiving first-line therapy in the United States veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: Nov 15-16, 2019.
109. Phatak H, Zheng Y, Bhanegaonkar A, Kim R, et al. Real-world clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) receiving first-line (1L) therapy in the US veteran population. *18th International Kidney Cancer Symposium (IKCS)*. Miami, FL: Nov 15-16, 2019.
110. Nicholls C, Wang Y, Westerbacka J, et al. Examining the temporal trends in hypoglycemia events, treatment adherence and A1c in patients with T2D in the US. *ISPOR Annual European Congress*. Copenhagen, Denmark: Nov 2-6, 2019.



111. Huang Q, Ellis L, Wang L, et al. Real-world evidence of ibrutinib use among patients with chronic lymphocytic leukemia and/or small lymphocytic lymphoma in the US Veteran Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: Oct 29 - Nov 1, 2019.
112. Shrestha S, Wang L, Chen G, et al. Development and validation of an administrative claims-based inflammatory bowel disease (IBD) severity index. *Academy of Managed Care Pharmacy (AMCP) Nexus 2019*. National Harbor, MD: Oct 29 - Nov 1, 2019.
113. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *14th Annual Cardiometabolic Health Congress*. Chicago, IL: Oct 10-13, 2019.
114. Patel C, Huang A, Wang L, et al. Journey of Veteran Health Administration population with recent schizophrenia diagnosis: A real-world analysis of treatment patterns and healthcare burden. *32nd Annual Psych Congress*. San Diego, CA: Oct 3-6, 2019.
115. Ng-Mak D, Kadakia A, Shrestha S, et al. Hospitalization risk in pediatric bipolar patients treated with lurasidone vs. other oral atypical antipsychotics: A real-world retrospective claims database study. *32nd Annual Psych Congress*. San Diego, CA: Oct 3-6, 2019.
116. Kambhampati S, Parasuraman S, Yu J, et al. Hematocrit (HCT) levels and thrombotic events (TEs) among US veterans with polycythemia vera (PV). *Association of VA Hematology/Oncology (AVAHO) Annual Meeting 2019*. Minneapolis, MN: Sept 20-22, 2019.
117. Huang Q, Ellis L, Wang L, et al. First-line ibrutinib treatment is associated with longer time to next treatment in a real-world US veterans population. *Society of Hematologic Oncology (SOHO) 2019 Annual Meeting*. Houston, TX: Sept 11-14, 2019.
118. Deitelzweig S, Keshishian A, Kang A, et al. Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: An ARISTOPHANES study analysis. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - Sept 1, 2019.
119. Deitelzweig S, Keshishian A, Kang A, et al. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - Sept 1, 2019.
120. Keshishian A, Lee T, Wygant G, et al. Patterns of extended apixaban treatment for unprovoked venous thromboembolism in routine clinical practice. *European Society of Cardiology (ESC) Congress 2019*. Paris, France: Aug 31 - Sept 1, 2019.
121. Neslusan C, Huang A, John J. et al. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *2019 VA/DoD Suicide Prevention Conference*. Nashville, TN: Aug 26-29, 2019.
122. Keshishian A, Lee T, Wygant G, et al. Anticoagulant treatment patterns among venous thrombosis patients with active cancer: a retrospective analysis using four US claims databases. *27th International Society on Thrombosis and Hemostasis (ISTH) Congress and 65th Annual Scientific Meeting 2019*. Melbourne, Australia: July 6-10, 2019.



123. Xie L, Kariburyo F, Sah J, et al. Real world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *European Congress of Rheumatology (EULAR) 2019*. Madrid, Spain: June 12-15, 2019.
124. Neslusan C, Sheehan JJ, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Society of Health-System Pharmacists (ASHP) Summer Meetings & Exhibition*. Boston, MA: June 8-12, 2019.
125. Chen J, Fan L, Juneja R, et al. Treatment patterns and outcomes before and after human regular U-500 insulin initiation via KwikPen in US veterans with type 2 diabetes. *American Diabetes Association (ADA) 79th Scientific Sessions*. San Francisco, CA: June 7-11, 2019.
126. Zheng Y, Pandya S, Yu T, et al. Real-world clinical and economic outcomes among newly-diagnosed merkel cell carcinoma (MCC) patients starting checkpoint inhibitors (CPIs) or chemotherapy (CT) in the Veterans Health Administration (VHA). *American Society of Clinical Oncology (ASCO) 2019 Annual Meeting*. Chicago, IL: May 31 - June 4, 2019.
127. Mavros P, Patel C, El Khoury A, et al. A real-world analysis of outcomes related to veterans with schizophrenia who transitioned to once-every-3-months paliperidone palmitate vs those who remained on once-monthly paliperidone palmitate. *American Society of Clinical Psychopharmacology (ASCP) Annual Meeting 2019*. Scottsdale, AZ: May 28-31, 2019.
128. Samuelson C, Lim J, Golembesky AK, et al. Retrospective claims analysis of treatment duration, healthcare resource utilization and costs associated with first-line treatment of NSCLC with afatinib vs erlotinib in the United States. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
129. Pennock G, Wang L, Pandya S. Real-world treatment patterns among metastatic renal cell carcinoma patients receiving first-line therapy in the United States veteran population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
130. Bhanegaonkar A, Kim R, Pandya S, et al. Real-world treatment patterns among metastatic urothelial cancer patients receiving second-line therapy in the US veteran population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Annual Meeting*. New Orleans, LA: May 18-22, 2019.
131. Lim S, Johnston S, Wang Y, et al. Evaluation of clinical and economic outcomes associated with staple line buttress among patients undergoing sleeve gastrectomy. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
132. Obando C, Ding Z, Muser E, et al. Evaluation of ustekinumab treatment patterns among Crohn's disease patients in three large US commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.
133. Neslusan C, Sheehan J, Wang L, Huang A. Characteristics of the Veterans Health Administration population diagnosed with major depressive disorder and suicidal ideation or suicide attempt. *American Psychiatric Association (APA) Annual Meeting*. San Francisco, CA: May 18-22, 2019.
134. Zhang Q, Delinger R, Wang H, et al. Assessing the risk factors of heart failure among patients in the US Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.



135. Wang H, Qiang W, Delinger R, et al. Examining the risk factors of chronic obstructive pulmonary disease among patients in the Department of Defense population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
136. Pan X, Chen CC, Wang L, et al. Real-world evidence of the economic burden and risk factors for hospitalization among patients with myeloma in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
137. Dieyi C, Pedarla V, Gu Y, et al. Assessing the economic burden and hospitalization among patients with non-alcoholic steatohepatitis in the US Veterans Health Administration population. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
138. Okunowo O, Li L, Pedarla V, et al. Assessing the economic burden and predictors of hospitalization among US veteran patients with rheumatoid arthritis: A retrospective case-control study. *ISPOR US Annual Meeting*. New Orleans, LA: May 18-22, 2019.
139. Obando C, Ding Z, Muser E, et al. Evaluation of health care utilization, hospitalization/emergency room costs, and other medication use among Crohn's disease patients using ustekinumab in three large United States commercial claims databases. *Digestive Disease Week (DDW)*. San Diego, CA: May 18-21, 2019.
140. Cole M, Lickert C, Drake W, et al. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within the Medicare population. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
141. Wang Y, Zhang Q, Xie L, et al. Overuse of short-acting bronchodilators and the risk of exacerbation among patients with chronic obstructive pulmonary disease (COPD) treated with nebulized short-acting bronchodilators. *American Thoracic Society (ATS) International Conference 2019*. Dallas, TX: May 17-22, 2019.
142. Keshishian A, Li X, Hamilton M, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: The dose subgroup analysis of the ARISTOPHANES study. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
143. Thieffry S, Borghs S, Wang L, et al. Characteristics, healthcare resource use and costs of overall pediatric focal epilepsy population and by comorbidity subgroup: A US claims database analysis. *71st American Academy of Neurology (AAN) Annual Meeting*. Philadelphia, PA: May 4-10, 2019.
144. Ramaswamy K, Lechpammer S, Mardekian J, et al. Survival rates and economic outcomes in chemotherapy-naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
145. Freedland SJ, Ramaswamy K, Lechpammer S, et al. Impact of prostate specific antigen doubling time on metastasis and increased costs associated with progression to metastatic castrate-resistant prostate cancer. *2019 Annual Meeting of the American Urological Association (AUA) Education and Research Inc*. Chicago, IL: May 3-6, 2019.
146. Xie L, Kariburyo F, Sah J, et al. Real world medication use in Incident systemic lupus erythematosus and lupus nephritis patients. *Congress of Clinical Rheumatology – East 2019*. Destin, FL: May 2-5, 2019.



147. Patel C, El Khoury A, Huang A, et al. A real-world analysis of transitioning from oral risperidone or paliperidone to once-monthly paliperidone palmitate among veterans with schizophrenia. *22nd Annual Meeting of the College of Psychiatric and Neurologic Pharmacists (CPNP)*. Salt Lake City, UT: April 7-10, 2019.
148. Hlavacek P, Guo JD, Rosenblatt L, et al. Effectiveness and safety of apixaban compared to warfarin among VTE patients in the US Medicare population. *American Heart Association (AHA) QCOR 2019*. Arlington, VA: April 5-6, 2019.
149. Hlavacek P, Guo JD, Rosenblatt L, et al. Comparison of costs among VTE patients initiating apixaban or warfarin in the US Medicare population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
150. El Khoury A, Patel C, Huang A, et al. Real-world outcomes among veterans severely affected by schizophrenia that transitioned from oral risperidone or paliperidone to once-monthly paliperidone palmitate. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
151. Pedarla V, Gu Y, Wang L, Baser O. Assessing economic burden and hospitalization among asthma patients in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
152. Zhang Q, Delinger R, Fang B, et al. Health care utilization and economic burden of multiple myeloma among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
153. Qiang W, Fang B, Delinger R, Keshishian A, Xie L. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
154. Pedarla V, Gu Y, Wang L, Baser O. Health care utilization and economic burden of type-2 diabetes among patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting*. San Diego, CA: March 25-28, 2019.
155. Pavilack M, Narendranath E, Andritsos L, et al. Healthcare costs and resource utilization associated with adverse events among hairy cell leukemia patients treated with purine nucleoside analogs. *National Comprehensive Cancer Network (NCCN) 2019 Annual Conference*. Orlando, FL: March 21-23, 2019.
156. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese non-valvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
157. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in obese nonvalvular atrial fibrillation patients: A pooled claims database analysis. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
158. Lip GYH, Keshishian A, Kang A, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants compared to warfarin among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.



159. Lip GYH, Keshishian A, Kang A, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants among frail nonvalvular atrial fibrillation patients. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
160. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran and rivaroxaban versus warfarin in obese patients with nonvalvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
161. Deitelzweig S, Keshishian A, Kang A, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in obese patients with non-valvular atrial fibrillation: ARISTOPHANES subgroup analysis. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
162. Chowdhury R, Franchino-Elder J, Wang L, et al. Health care resource utilization and expenditures among newly diagnosed non-valvular atrial fibrillation patients initiating oral anticoagulants: Results from 100% Medicare 2010-2015 data. *American College of Cardiology's (ACC) 68th Annual Scientific Session & Expo*. New Orleans, LA: March 16-18, 2019.
163. Parasuraman S, Yu J, Paranagama D, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *European School of Haematology: How to Diagnose and Treat CML/MPN*. Saggart, Ireland: March 8-10, 2019.
164. Armstrong AW, Gadkari A, Mallya UG, et al. The economic burden associated with time to therapy escalation for patients with atopic dermatitis uncontrolled with topical therapies. *American Academy of Dermatology (AAD) Annual Meeting*. Washington, DC: March 1-5, 2019.
165. Freedland SJ, Ramaswamy K, Lechpammer S, et al. Impact of prostate specific antigen doubling time on time to metastasis and overall survival in non-metastatic castration-resistant prostate cancer patients. *American Society of Clinical Oncology-Genitourinary Cancers Symposium*. San Francisco, CA: Feb 14-16, 2019.
166. Zheng Y, Pandya S, Yu T, et al. Emerging treatment patterns and checkpoint inhibitor use among newly-diagnosed merkel cell carcinoma patients in the US veteran population. *ASCO-SITC Clinical Immuno-Oncology Symposium*. San Francisco, CA: Feb 8 - March 2, 2019.
167. Dahhan T, Cole M, Lickert C, et al. Baseline demographics and clinical characteristics of chronic thromboembolic pulmonary hypertension patients within Medicare population. *13th Pulmonary Vascular Research Institute (PVRI) Annual World Congress on Pulmonary Vascular Disease (PVD)*. Barcelona, Spain: Jan 30 - Feb 3, 2019.
168. Epperla N, Pavilack M, Olufade T, et al. Adverse events among patients with hairy cell leukemia treated with purine nucleoside analogs in the United States. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
169. Pandya S, Clancy Z, Shrestha S, Wang L, Baser O. Burden of CRAB events by relapse in patients with newly diagnosed multiple myeloma not eligible for stem cell transplant. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.



170. Parasuraman S, Baser O, Sturm D, et al. Elevated white blood cell levels and thrombotic events in patients with polycythemia vera: A real-world analysis of Veterans Health Administration data. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
171. Levy M, Xie L, Wang Y, et al. Real-world comparisons of cardiovascular events between different tyrosine kinase inhibitors among patients with chronic myeloid leukemia. *American Society of Hematology (ASH) Annual Meeting*. San Diego, CA: Dec 1-4, 2018.
172. Deitelzweig S, Keshishian A, Li X, et al. Effectiveness and safety of novel oral anticoagulants among patients with nonvalvular atrial fibrillation and diabetes: A pooled claims database analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
173. Deitelzweig S, Keshishian A, Li X, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin among patients with non-valvular atrial fibrillation and diabetes: ARISTOPHANES diabetes subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
174. Lip GHY, Keshishian A, Li X, et al. Non-vitamin K antagonist oral anticoagulants associated with lower stroke rates compared to warfarin among very elderly patients with non-valvular atrial fibrillation: An ARISTOPHANES subgroup analysis. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
175. Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants among very elderly patients with non-valvular atrial fibrillation: An observational study. *American Heart Association (AHA) Scientific Sessions 2018*. Chicago, IL: Nov 10-12, 2018.
176. Xie L, Sun X, Mallampati R, et al. Healthcare utilization and economic burden on patients with bladder cancer in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Congress 2018*. Barcelona, Spain: Nov 10-14, 2018.
177. Borra S, Lin C, Wang L, Yuce H, Baser O. Assessing the economic burden and 30-day readmission rates among patients with bladder cancer in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) European Congress 2018*. Barcelona, Spain: Nov 10-14, 2018.
178. Szukis H, Benson C, Huang A, et al. Economic burden of illness among US veterans with treatment-resistant depression. *US Psych Congress 2018*. Orlando, FL: Oct 25-28, 2018.
179. Patel C, El Khoury A, Huang A, et al. Outcomes related to transition to once-every-three-monthly paliperidone palmitate among veterans with schizophrenia. *US Psych Congress 2018*. Orlando, FL: Oct 25-28, 2018.
180. George D, Schultz N, Huang A, et al. Increased costs associated with progression to metastatic castrate-resistant prostate cancer. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
181. Ramaswamy K, Mardekian J, Schultz N, et al. Economic burden of chemotherapy naïve metastatic castrate resistant prostate cancer patients treated with abiraterone acetate or enzalutamide in the United States. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.



182. Amin A, Keshishian A, Dina O, et al. Healthcare costs of direct oral anticoagulants vs warfarin among Medicare patients with non-valvular atrial fibrillation. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
183. Amin A, Keshishian A, Dina O, et al. Elderly patients with non-valvular atrial fibrillation incurred lower all-cause, stroke, and major bleeding-related costs when treated with apixaban versus dabigatran, rivaroxaban, and warfarin treatment. *Academy of Managed Care Pharmacy (AMCP) Nexus 2018*. Orlando, FL: Oct 22-25, 2018.
184. Xie L, Kariburyo F, Sah J, et al. Real-world medication use in incident systemic lupus erythematosus and lupus nephritis patients. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: Oct 19-24, 2018.
185. Katz NP, Gandhi K, Wei W, et al. Assessing inappropriate pain management in adults with hip or knee osteoarthritis treated with different opioid intensity regimens: Results from a retrospective database analysis. *American College of Rheumatology (ACR) / ARHP Annual Meeting*. Chicago, IL: Oct 19-24, 2018.
186. Bhor M, Xie L, Arcona S, et al. Rate of vaso-occlusive crisis episodes among sickle cell disease patients in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: Oct 10-13, 2018.
187. Bhor M, Xie L, Paulose J, et al. Primary reasons for sickle-cell disease-related hospital and emergency room visits in the US Medicaid population. *Sickle Cell Disease Association of America (SCDAA) 46th Annual National Convention for Sickle Cell Disease*. Baltimore, MD: Oct 10-13, 2018.
188. Pandya S, Shrestha S, Wang L, et al. Real-world economic outcomes of early progression in newly diagnosed multiple myeloma (NDMM) patients. *2018 American Society of Clinical Oncology (ASCO) Quality Care Symposium*. Phoenix, AZ: Sept 28-29, 2018.
189. Katz NP, Wei W, Gandhi K, et al. A real-world study of treatment regimen failure by opioid use intensity among patients with hip and/or knee osteoarthritis. *International Association for the Study of Pain (IASP) The 17th World Congress on Pain*. Boston, MA: Sept 12-16, 2018.
190. Amin A, Keshishian A, Zhang Q, et al. Effectiveness, safety, and composite clinical outcomes of apixaban, dabigatran, rivaroxaban, relative to warfarin in non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
191. Deitelzweig S, Keshishian A, Li X, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients: the dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
192. Lip GYH, Keshishian A, Li X, et al. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants and warfarin among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.



193. Amin A, Keshishian A, Zhang Q, et al. Effectiveness, safety, and composite clinical outcomes between apixaban and other oral anticoagulants for non-valvular atrial fibrillation patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
194. Deitelzweig S, Keshishian A, Li X, et al. Comparisons of clinical and economic outcomes between non-VKA oral anticoagulants among non-valvular atrial fibrillation patients: the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
195. Amin A, Bassalobre Garcia A, Li X, et al. Comparison of effectiveness, safety, and healthcare costs in nonvalvular atrial fibrillation patients with heart failure prescribed direct oral anticoagulants. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
196. Lip GYH, Keshishian A, Li X, et al. Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients: a dose subgroup analysis of the ARISTOPHANES study. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
197. Lopes RD, Steffel J, Di Fusco M, et al. Standard and reduced doses of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
198. Lopes RD, Steffel J, Di Fusco M, et al. Effectiveness and safety of direct oral anticoagulants versus warfarin in elderly patients with non-valvular atrial fibrillation according to coronary artery disease and/or peripheral artery disease. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
199. Amin A, Bassalobre Garcia A, Li X, et al. Comparison of effectiveness, safety, and healthcare costs of direct oral anticoagulants with warfarin in non-valvular atrial fibrillation patients with heart failure. *European Society of Cardiology (ESC) Congress 2018*. Munich, Germany: Aug 25-29, 2018.
200. Cohen J, Beaubrun A, Bashyal R, et al. Real-world persistence for newly prescribed HIV-1 treatment: Single versus multiple tablet regimen comparison. *34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)*. Prague, Czech Republic: Aug 22-26, 2018.
201. Coleman CI, Herman WH, Pandya S, et al. Body weight outcomes with canagliflozin 300 mg (CANA) vs glucagon-like peptide-1 receptor agonists (GLP-1s) in a real-world setting. *American Diabetes Association (ADA) 78th Scientific Sessions*. Orlando, FL: June 22-26, 2018.
202. Rubin DT, Long MD, Keshishian A, et al. The impact of intestinal complications on healthcare costs among inflammatory bowel disease patients with anti-TNF therapies. *Digestive Disease Week (DDW)*. Washington, DC: June 2-5, 2018.
203. Obando C, Xie L, Vaidya N, Sah J. Evaluate the treatment patterns and healthcare utilizations for biologic therapies for Crohn's disease. *Digestive Disease Week*. Washington, DC: June 2-5, 2018.
204. Pandya S, Clancy Z, Shrestha S, et al. Economic burden of early progression in newly-diagnosed multiple myeloma patients. *2018 American Society of Clinical Oncology (ASCO) Annual Meeting*. Chicago, IL: June 1-5, 2018.



205. Gupta A, Lin C, Wang L, et al. Assessing the economic burden and 30-day readmission rates among patients with chronic obstructive pulmonary disease in the US Veterans Health Administration population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
206. Xie L, Wang Y, Qiang W, et al. Health care utilization and economic burden of patients with inflammatory bowel disease in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
207. Bhor M, Wang Y, Xie L, et al. Poor medication adherence and high rates of treatment discontinuation among SCD patients treated with hydroxyurea. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
208. Bhor M, Wang Y, Xie L, et al. Relationship between pain crisis and life-threatening complications in sickle cell disease: A retrospective claims based study. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 23rd International Meeting*. Baltimore, MD: May 19-23, 2018.
209. Parasuraman S, Yu J, Paranagama D, et al. Hematocrit (HCT) levels and thrombotic events (TEs) among US Veterans with polycythemia vera (PV). *European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasm*. Saggart, Ireland: May 15-17, 2018.
210. Bhor M, Wang Y, Xie L, et al. Clinical burden and management of sickle cell disease among pediatric patients. *The 2018 American Society of Pediatric Hematology/Oncology (ASPHO) Conference*. Pittsburgh, PA: May 2-5, 2018.
211. Huang A, Wei W, Gandhi K, et al. Opioid use intensity and its association with opioid overdose risk and abuse and hospitalization among patients with hip/knee osteoarthritis: A retrospective analysis of real-world data. *American Academy of Pain Medicine's (AAPM) 34th Annual Meeting*. Vancouver, Canada: April 26-29, 2018.
212. Xie L, Baser O, Wang Y, et al. Health care utilization and economic burden on patients diagnosed with epilepsy in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. April 23-26, 2018: Boston, MA.
213. Borra S, Lin C, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with breast cancer in the US Veterans Health Administration population. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.
214. O'Neal W, Mendes S, Baser O, et al. Adherence and outpatient resource use with extended-release oxcarbazepine (Oxtellar XR[®]) vs immediate-release oxcarbazepine (OXC-IR): Analysis of pooled data from four national claims databases. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2018*. Boston, MA: April 23-26, 2018.
215. Fishman J, Shrestha S, Wang L, et al. Impact of Medicaid antiepileptic drug formulary restrictions on health outcomes and costs. *2018 American Academy of Neurology (AAN) Annual Meeting*. Los Angeles, CA: April 21-27, 2018.



216. Deitelzweig S, Keshishian A, Li X, et al. Comparison of effectiveness, safety, and the net clinical outcome between different direct oral anticoagulants in 162,707 non-valvular atrial fibrillation patients treated in US clinical practice. *American College of Cardiology (ACC) 67th Annual Scientific Session & Expo*. Orlando, FL: March 10-12, 2018.
217. Pandya S, Wang L, Baser O, et al. The burden of hypoxic respiratory failure in preemies and neonates in the United States: 2011-2015. *Hot Topics in Neonatology*. Washington, DC: Dec 11-13, 2017.
218. Huntington S, Keshishian A, Xie L, et al. Real-world patterns of care for patients with follicular lymphoma treated with lenalidomide and rituximab (R2) in the US Medicare population. *American Society of Hematology (ASH) Annual Meeting*. Atlanta, GA: Dec 9-12, 2017.
219. Gupta K, Mardekian J, Shank T, et al. Comparisons of all-cause, stroke- and major bleeding-related medical costs among non-valvular atrial fibrillation patients who initiated oral anticoagulation therapies in the US Department of Defense Military Health System. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
220. Amin A, Keshishian A, Trocio J, et al. Risk of stroke and major bleeding for dabigatran, rivaroxaban, and warfarin compared to apixaban among non-valvular atrial fibrillation patients in the United States Medicare population. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
221. Deitelzweig S, Keshishian A, Li X, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban among non-valvular atrial fibrillation patients: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
222. Lopes RD, Di Fusco M, Keshishian A, et al. Effectiveness and safety of apixaban versus other oral anticoagulants in older adults with non-valvular atrial fibrillation and concomitant coronary artery disease or peripheral arterial disease. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
223. Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of apixaban compared to other anticoagulants among non-valvular atrial fibrillation patients with coronary artery disease or peripheral arterial disease: A propensity score matched analysis of four large databases. *American Heart Association (AHA) Scientific Sessions 2017*. Anaheim, CA: Nov 11-15, 2017.
224. Xie L, Zhou FL, Pan C, et al. Impact of treatment persistence on glycated haemoglobin A1c (HbA1c) trends among patients with type 2 diabetes newly initiated on basal insulin. *53rd European Association for the Study of Diabetes Annual Meeting*. Lisbon, Portugal: Sept 11-15, 2017.
225. Xie L, Zhou L, Kariburyo F, et al. Clinical outcomes of patients with type 2 diabetes who switched to insulin glargine 300 U/ml from insulin glargine 100 U/ml in real world US treatment settings. *Association of British Clinical Diabetologists (ABCD) Autumn Meeting*. London, UK: Nov 10, 2017.
226. Zhang Q, Kariburyo MF, Xu J, et al. Examining health care utilization and costs among atherosclerosis patients in the US Veteran Health Administration population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.



227. Wang L, Lewis-Black C, Fritschel E, Baser E. Comparison of various meta-analysis techniques. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
228. Ogbomo A, Lin Y, Keshishian A, et al. A comparative analysis of the health care utilization and costs of patients diagnosed with and without liver cancer in the US Medicare population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
229. Vaidya N, Wang Y, Xie L, Baser O. Evaluating the economic burden and health care utilization of bacterial pneumonia in the US Department of Defense population. *ISPOR 20th Annual European Congress*. Glasgow, Scotland: Nov 4-8, 2017.
230. Yazici Y, Simsek I, Xie L, et al. A real-world analysis of treatment patterns in a Turkish rheumatology population with continuous infliximab therapy or switched to biosimilar infliximab. *American College of Rheumatology (ACR) 2017 Annual Meeting*. San Diego, CA: Nov 3-8, 2017.
231. Nazareth T, Kariburyo F, Kirkemo A, et al. Focal segmental glomerulosclerosis: A claims analysis of clinical and economic outcomes. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: Oct 31 - Nov 5, 2017.
232. Nazareth T, Kariburyo F, Kirkemo A, et al. Membranous nephropathy: A real-world clinical and economic analysis. *American Society of Nephrology (ASN) Kidney Week 2017*. New Orleans, LA: Oct 31 - Nov 5, 2017.
233. Ariely R, Chipps BE, Stoyanov S, et al. Budgetary impact model on a Medicare plan adopting short-acting beta-agonist inhalers with integrated dose counters. *2017 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology*. Boston, MA: Oct 26-30, 2017.
234. Shah A, Xie L, Kariburyo F, et al. Real-world comparison of treatment patterns, health care resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
235. Mutlu E, Ogbomo A, Goyal K, Ellis L. Real-world utilization of biosimilar and originator infliximab in a cohort of patients with inflammatory bowel disease in Turkey. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
236. Ellis L, Simsek I, Xie L, et al. Analysis of real-world treatment patterns in a matched sample of rheumatology patients with continuous infliximab therapy or switched to biosimilar infliximab. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
237. Hall E II, Wells W, Teynor M, et al. Healthcare resource utilization and costs of spinal muscular atrophy care in the US Medicaid population. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
238. Zhou FL, Xie L, Wang Y, et al. Lower hypoglycemia risk and better persistence in adults with type 2 diabetes after switch to insulin glargine 300 U/mL vs other basal insulins in real-world clinical settings. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.
239. Kerwin EM, Stoyanov S, Wang L, et al. The budget impact on the adoption of short-acting beta-agonist inhalers with integrated dose counters in managed care. *Academy of Managed Care Pharmacy (AMCP) Nexus 2017*. Dallas, TX: Oct 16-19, 2017.



240. Duncan M, Wang Y, Xie L, et al. Prevalence and treatment patterns of opioid use disorder in two commercial populations. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
241. Shah A, Xie L, Kariburyo F, et al. Treatment patterns, healthcare resource utilization and costs in schizophrenia patients treated with long-acting injectable vs oral antipsychotics: A real-world study. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
242. Zhao Q, Wang L, Kurlansky PA, et al. Impact of coronary artery disease on clinical outcomes among patients with newly-diagnosed heart failure with systolic dysfunction: Is it changing over time? *Heart Failure Society of America (HFSA) 21st Annual Scientific Meeting*. Dallas, TX: Sept 16-19, 2017.
243. Benson C, Huang A, Wang L, et al. Clinical and economic burden of major depressive disorder among US veterans. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
244. Huang A, Amos T, Joshi K, et al. Burden of schizophrenia in recently diagnosed adult patients: A commercial payer perspective. *US Psych Congress 2017*. New Orleans, LA: Sept 16-19, 2017.
245. Zhang Q, Xie L, Baser O, McGuire M. Evaluating treatment patterns of relapsed acute myeloid leukemia among the elderly in the United States. *Society of Hematologic Oncology (SOHO) Annual Meeting*. Houston, TX: Sept 13-16, 2017.
246. Taylor K, Araujo AB, Wang L, et al. Effectiveness of a private, orthopedic practice-based osteoporosis management program for prevention of recurrent fractures. *American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting*. Denver, CO: Sept 8-11, 2017.
247. Amin A, Keshishian A, Trocio J, et al. Risk of major bleeding among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
248. Lip GYH, Keshishian A, Li X, et al. Predictors of warfarin discontinuation or switching among non-valvular atrial fibrillation patients. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
249. Li X, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin among high-risk subgroups of non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
250. Li X, Lip GYH, Keshishian A, et al. Effectiveness and safety of standard and lower dose apixaban compared to warfarin in non-valvular atrial fibrillation patients: a propensity score matched analysis. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
251. Zhao Q, Wang L, Kurlansky PA, et al. Short and intermediate term all-cause mortality among newly-diagnosed heart failure patients in the US Medicare population. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.
252. Peacock WF, Coleman C, Wells P, et al. Clinical and economic outcomes in low-risk pulmonary embolism patients treated with rivaroxaban vs standard of care. *European Society of Cardiology (ESC) Congress 2017*. Barcelona, Spain: Aug 26-30, 2017.



253. Pandya S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with heart failure in the US Veterans Health Administration population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
254. Zhang Q, Xie L, Keshishian A, et al. Examining the health care utilization and costs among elderly patients with chronic obstructive pulmonary disease in the United States. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
255. Vaidya N, Xie L, Wang Y, et al. Evaluating the economic burden and health care utilization of migraine in the US Department of Defense population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
256. Ogbomo A, Keshishian A, Xie L, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with multiple myeloma in the US Medicare population. *International Society for Pharmacoepidemiology (ISPE) 33rd International Conference on Pharmacoepidemiology*. Montreal, Canada: Aug 26-30, 2017.
257. Wells P, Peacock WF, Fermann GJ, et al. The value of sPESI for risk stratification in patients with pulmonary embolism. *International Society on Thrombosis and Hemostasis (ISTH) 2017*. Berlin, Germany: July 8-13, 2017.
258. Phillips K, Juday T, Zhang Q, Keshishian A. Economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed Infliximab or CT-P13 in the Turkish population. *European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology*. Madrid, Spain: June 14-17, 2017.
259. Kuritzkes BA, Pappou EP, Guo X, et al. Visceral fat area, not body mass index, predicts postoperative 30-day morbidity in patients undergoing colon resection for cancer. *American Society of Colon and Rectal Surgeons (ASCRS) 2017 Annual Scientific and Tripartite Meeting*. Seattle, WA: June 10-14, 2017.
260. Zhou F, Xie L, Pan C, et al. Impact of treatment persistence on A1C trends among patients with T2D newly initiated on basal insulin. *American Diabetes Association (ADA) 77th Scientific Sessions*. San Diego, California: June 9-13, 2017.
261. Xie L, Zhang Q, Baser O, McGuire M. Examining the health care resource use and economic costs associated with acute myeloid leukemia among Medicare patients. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
262. Du J, Xie L, Keshishian A, et al. Assessing the hospital readmission and mortality rates among elderly patients with chronic obstructive pulmonary disease. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
263. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with clostridium difficile infection in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
264. Ogbomo A, Lin Y, Wang Y, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with lymphoma in the US Medicare population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.



265. Lin Y, Ogbomo A, Wang Y, et al. A descriptive analysis of the health care utilization and costs of patients diagnosed with myelodysplastic syndrome in the US Medicare population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
266. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with pneumonia in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
267. Xie L, Vaidya N, Wang Y, et al. Evaluating the economic burden and health care utilization of prostate cancer patients in the US Department of Defense population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
268. Vaidya N, Tan H, Xie L, et al. Evaluating the economic burden and health care utilization of rheumatoid arthritis patients in the US Department of Defense population. *International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
269. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *ISPOR 22nd Annual International Meeting*. Boston, MA: May 20-24, 2017.
270. Borra S, Cao Y, Wang L, Baser O. Assessing the economic burden and 30-day readmission rates among patients with urinary tract infection in the US Veterans Health Administration population. *International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting*. Boston MA: May 20-24, 2017.
271. Ganapathy V, Xie L, Keshishian A, et al. Continuing care with nebulized bronchodilators after hospital discharge and impact on readmissions: Analysis of Medicare COPD beneficiaries receiving arformoterol vs nebulized short-acting agents. *American Thoracic Society (ATS) International Conference 2017*. Washington, DC: May 19-24, 2017.
272. Black CM, Fillit H, Xie L, et al. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
273. Black CM, Fillit H, Xie L, et al. Rates of institutionalization among newly-diagnosed Alzheimer's disease patients. *American Academy of Neurology (AAN) 69th Annual Meeting*. Boston, MA: April 22-28, 2017.
274. Wang L, Baser O, Wells P, et al. Predictors of hospital length of stay among patients with low-risk pulmonary embolism. *Society of General Internal Medicine (SGIM) 2017 Annual Meeting*. Washington, DC: April 19-22, 2017.
275. Nazareth T, Kariburyo F, Pirani A, et al. Patients with nephrotic syndrome (NS) receiving repository corticotrophin injection (RCI) or rituximab (RTX): Real-world evidence from a US claims analysis. *National Kidney Foundation (NKF) 2017 Spring Clinical Meetings*. Orlando, FL: April 18-22, 2017.
276. Xie L, Parikh K, Abouzaid S, et al. Real-world treatment outcomes and costs among newly-diagnosed multiple myeloma patients treated with bortezomib and dexamethasone in combination with cyclophosphamide or lenalidomide. *13th Hematology/ Oncology Pharmacy Association (HOPA) Annual Conference*. Anaheim, CA: March 29 - April 1, 2017.



277. Black CM, Fillit H, Xie L, et al. Rates of institutionalization among newly diagnosed Alzheimer's disease patients. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: March 29 - April 2, 2017.
278. Black CM, Fillit H, Xie L, et al. Cognition and activity impairment of newly diagnosed Alzheimer's disease patients in the Medicare Minimum Data Set. *13th International Conference on Alzheimer's & Parkinson's Diseases*. Vienna, Austria: March 29 - April 2, 2017.
279. Lee S, Xie L, Wang Y, Baser O. Evaluating the impact of treatment persistence on the economic burden of moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
280. Ye F, Zhou FL, Xie L, et al. Clinical outcomes of patients with type 2 diabetes (T2D) who switched to insulin glargine 300 U/mL (Gla-300) from insulin glargine 100 U/mL (Gla-100) in real-world US treatment settings. *Academy of Managed Care Pharmacy (AMCP) Managed Care Specialty Pharmacy Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
281. Ganapathy V, Xie L, Wang Y, et al. Prescription fill patterns after reaching the Medicare Part D coverage gap among chronic obstructive pulmonary disease patients on maintenance bronchodilators. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
282. Chipps B, Ferro T, Wang L, et al. Healthcare costs in asthma and/or chronic obstructive pulmonary disease patients using albuterol inhalation aerosol with and without an integrated dose counter. *Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2017*. Denver, CO: March 27-30, 2017.
283. Pandya S, Abouzaid S, Xie L, et al. Real-world health care costs among newly-diagnosed multiple myeloma patients in the United States veteran population (FY 2011-2015). *National Comprehensive Cancer Network (NCCN) 22nd Annual Conference*. Orlando, FL: March 23-25, 2017.
284. Amin A, Keshishian A, Trocio J, et al. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban compared to warfarin among non-valvular atrial fibrillation patients in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: March 17-19, 2017.
285. Amin A, Keshishian A, Vo L, et al. Real-world comparison of major bleeding and associated costs among oral anticoagulant-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarin in the US Medicare population. *American College of Cardiology (ACC) 66th Annual Scientific Session & Expo*. Washington, DC: March 17-19, 2017.
286. Ganapathy V, Xie L, Wang Y, et al. Hospital readmissions among chronic obstructive pulmonary disease patients treated in skilled nursing facilities in the US. *AMDA (Society for Post-acute and Long-term Care Medicine) Annual Conference 2017*. Phoenix, AZ: March 16-19, 2017.
287. Lee S, Xie L, Wang Y, Baser O. Evaluating the economic burden and incidence of comorbidities among moderate-to-severe PsO and/or PsA patients in the US Department of Defense population. *American Academy of Dermatology (AAD) 2017 Annual Meeting*. Orlando, FL: March 3-7, 2017.



288. Shrestha S, Baser O, Zhou X, Kwong WJ. Inappropriate dosing of oral anticoagulants among patients with non-valvular atrial fibrillation. *American Heart Association (AHA) International Stroke Conference (ISC) 2017*. Houston, TX: February 22-24, 2017.
289. Sonpavde G, Huang A, Wang L, et al. First-line chemotherapy (CT) versus anti-androgen therapy (AT) for patients with metastatic castration-resistant prostate cancer (mCRPC): Individual patient analysis of the Veterans Health Administration (VHA) dataset. *2017 Genitourinary Cancers Symposium*. Orlando, FL: Feb 16-18, 2017.